Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 12, 2007

Roche to Make $7.5M Milestone Payment to Pharmasset

  • Pharmasset and Roche have initiated long-term chronic toxicology studies in two animal species for the development of a HCV candidate as part of their collaboration. Roche will pay $7.5 million as a milestone fee. The compound, R7128, is currently in a Phase I trial. The primary objective of the toxicology research is to assess the safety of the drug when given for six months.

    "As we progress with the ongoing 14-day multiple ascending dose study of R7128, we are encouraged that Roche has initiated the long-term chronic toxicology studies in support of the potential advancement of R7128 into Phase II clinical trials," states Schaefer Price, Pharmasset's president and CEO.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »